Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS G12V T cell engager (A*03)
- Development stage
- Unknown
- Lead developer
- MyriO Tx
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KRAS G12V T cell engager (A*03) is a bispecific T-cell engager (BiTE) being developed by Myrio Therapeutics (MyriO Tx). It is designed to target the KRAS G12V mutation, a common oncogenic driver in various solid tumors, specifically when the mutant peptide is presented by the Human Leukocyte Antigen (HLA) allele A*03 on the surface of tumor cells. The therapeutic molecule is engineered to simultaneously bind to the KRAS G12V/HLA-A*03 complex and the CD3 receptor on T cells, facilitating the formation of an immunological synapse. This interaction leads to the localized activation of T cells and the subsequent targeted lysis of cancer cells. The drug is currently in the discovery phase for the treatment of lung, pancreatic, and colon cancers.
- Other names
- KRAS G12V T cell engager A*03KRAS (G12V) T Cell Engager (A*03)
02
Targets
KRAS G12V/HLA-A*03:01 (KRAS G12V peptide-HLA-A*03:01 complex)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on KRAS G12V T cell engager (A*03).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS G12V T cell engager (A*03).